Skip to main content

Non-profit launches COVID-19 treatment and vaccine tracker with daily updates

There are a lot of global efforts underway to develop vaccines and treatments for COVID-19, including repurposing of existing drugs approved for use in treating other forms of coronavirus and respiratory diseases. Many of these efforts are just entering into the formal clinical study phase, which will be required before any treatment is certified for widespread use in patients diagnosed with the illness. Vaccines are still likely at least a year out from approvals, though some have already entered into clinical human trials at unprecedented speed owing to the unprecedented nature of the pandemic.

It’s definitely a challenge to keep up with all the existing efforts to pursue effective treatments and develop vaccines, but public health non-profit the Milken Institute has a new resource that aims to keep track of at least the efforts from leading research institutions and drug makers. Their COVID-19 treatment and vaccine tracker currently offers a list of nearly 60 treatments, as well as 43 vaccines in development.

This list details the type of treatment or vaccine being studied or developed, as well as their FDA-approved status (for other conditions – none have been approved specifically for treating COVID-19 to date). They also indicate who is doing the drug development or research, and what stage the research project is at (either pre-clinical or clinical). The table lists the source of funding, if available, as well as the anticipated timetable for the phases of the project if known. It provides sourcing for each, as well, including credible media sources, journals and the World Health Organization.

This kind of tracker is a good resource for anyone looking to keep tabs on the ongoing work that people are doing to take on COVID-19, though it’s a high-level view that is probably of most interest to other ongoing projects, as well as health and research professionals who might be able to assist in the development of these solutions, or to collaborate with partners. The Milken Institute says that it’s going to be updating the tracker daily at noon eastern with any additional fresh info from reliable sources.

As mentioned, even vaccines that are already in development, like the mRNA-based immune therapy that began human trials last week in the U.S., will take many months to come to market, and they still have to demonstrate their effectiveness, too. In the meantime, people should do everything they can to isolate and remain indoors in order to help buy time for the healthcare system to develop treatments that can mitigate the impact of the disease, and eventually, ways to introduce immunity in order to block its transmission.



from TechCrunch https://ift.tt/2wzejWu
Labels:

Comments

Post a Comment

Popular posts from this blog

HPE is buying Cray for $1.3 billion

HPE announced it was buying Cray for $1.3 billion, giving it access to the company’s high performance computing portfolio, and perhaps a foothold into quantum computing in the future. The purchase price was $35 a share, a $5.19 premium over yesterday’s close of $29.81 a share. Cray was founded in the 1970s and for a time represented the cutting edge of super computing in the United States, but times have changed, and as the market has shifted, a deal like this makes sense. Ray Wang, founder and principal analyst at Constellation Research says this is about consolidation at the high end of the market. “This is a smart acquisition for HPE. Cray has been losing money for some time but had a great portfolio of IP and patents that is key for the quantum era,” he told TechCrunch. While HPE’s president and CEO Antonio Neri didn’t see it in those terms, he did see an opportunity in combining the two organizations. “By combining our world-class teams and technology, we will have the oppor...
Post a Comment
Read more

Apple rolls out Apple Card Preview to select users

Apple Card is getting its first group of public test users today. A limited amount of customers that signed up to be notified about the release of Apple Card are getting the ability to apply for the card in their Wallet app today — as well as the option to order their physical Apple Card. I’ve been using the card for a few days on my own device, making purchases and payments and playing around with features like Apple Cash rewards and transaction categorization. A full rollout of Apple Card will come later in August. It requires iOS 12.4 and up to operate. The application process was simple for me. Portions of the information you need are pre-filled from your existing AppleID account, making for less manual entry. I had an answer in under a minute and was ready to make my first purchase instantly. I used it both online and in person with contactless terminals. It…works. The card on the screen has a clever mechanism that gives you a sort of live heat map of your spending categorie...
1 comment
Read more

Moda Operandi, an online marketplace for high-end fashion, raises $100M led by NEA and Apax

Moda Operandi , an online marketplace for luxury fashion, accessories and home decor, is today announcing a high-priced event of its own: it’s raised $100 million, a mix of equity and debt that it will use to invest in its platform and technology as well as to continue growing business overall, which was founded in 2010 and today offers products from some 1,000 brands and designers and ships to 125 countries. “For the past eight years, Moda has disrupted the way people shop for luxury fashion,” said Moda Operandi CEO Ganesh Srivats in a statement. “This investment will enable us to build on that innovation, investing further in the client and designer experience and connecting more of the world’s best fashion to more people.” The financing is being co-led by NEA and Apax Partners, both previous investors in Moda Operandi, with participation also from the Santo Domingo Family (connected to Lauren Santo Domingo , who co-founded the company with Aslaug Magnusdottir ), Comerica Bank...
Post a Comment
Read more